Dr. Schwartz CEO of SKLN and Dr. Garvin with CytoBioscience Discuss Positive Results of a Merger in Progress with Their Two C...
August 16 2017 - 9:00AM
Dr. Schwartz CEO of SKLN and Dr. Garvin with CytoBioscience
Discuss Positive Results of a Merger in Progress with Their Two
Companies
Eagan, MN (UPTICK Newswire – August 16, 2017) - CEO Dr. Carl
Schwartz of Skyline Medical Inc. (NASDAQ: SKLN), a medical
technology company, and Dr. Jim Garvin with CytoBioscience, a
company in the human cell research on new therapeutic drug
development, were both interviewed on the Uptick Network Stock Day
Podcast with host Everett Jolly. Dr. Schwartz and Dr. Garvin both
discuss positive outcomes for a merger involving the two companies
and when this transaction could be completed. Both companies speak
on their partnership strategies, what both organizations bring to
the table for one another and what the companies are planning
together with this merger. Dr. Garvin briefly touches on past
company revenues and the future potential for revenue growth while
Dr. Schwartz touches bases on high hopes for Skyline Medical’s
fourth quarter.
In a closing statement Dr. Jim Garvin states, “We have risked a
fair amount of our time and good fortune in being able to build
this company and get it into a position where we can get into a
relationship like Skyline. My team, myself, my investors really
believe in this product set, they believe in this transaction and
they believe in Skyline,” Dr. Garvin continues, “I think there’s a
real opportunity here for investors to come along to what I think
is going to be a really wonderful ride and I’m saying this because
I believe it with all my heart.”
Dr. Schwartz agrees, “I believe that very much and concur with
what Dr. Garvin has said and we think we are in for an exciting
ride. CytoBioscience is a wonderful company, it will fit well with
Skyline and we both expect substantial growth in the next few
years, so keep an eye on us.”
To listen to the interview please click here or the following
link:
https://upticknewswire.com/iinterview-ceo-paul-danner-of-alliance-mma-inc-nasdaq-amma
About Skyline Medical
Skyline Medical produces a fully automated, patented,
FDA-cleared waste fluid disposal system that virtually eliminates
staff exposure to blood, irrigation fluid and other potentially
infectious fluids found in the healthcare environment. Antiquated
manual fluid handling methods that require hand carrying and
emptying filled fluid canisters present an exposure risk and
potential liability. Skyline Medical's STREAMWAY System fully
automates the collection, measurement and disposal of waste fluids
and is designed to: 1) reduce overhead costs to hospitals and
surgical centers; 2) improve compliance with OSHA and other
regulatory agency safety guidelines; 3) improve efficiency in the
operating room, and radiology and endoscopy departments, thereby
leading to greater profitability; and 4) provide greater
environmental stewardship by helping to eliminate the approximately
50 million potentially disease-infected canisters that go into
landfills each year in the U.S. For additional information,
please visit www.skylinemedical.com.
About
CytoBioscience
CytoBioscience creates and manufactures devices that represent a
convergence of bioscience, nanoscience, microchip development,
algorithms and engineering. The company’s devices allow
researchers, medical institutions and pharmaceutical companies to
better understand how human cells react to medicine.
CytoBioscience has a world-renown scientific and technical staff,
collaborative partnerships with leading pharmaceutical companies
and strategic alliances with key groups and academic institutions,
and its technology is used exclusively by the FDA. The
company was founded in Germany and moved its headquarters and
manufacturing to San Antonio, Texas in 2015. For additional
information, please visit www.cytobioscience.com.
Forward-looking StatementsCertain of the
matters discussed in this announcement contain forward-looking
statements that involve material risks to and uncertainties in the
Company's business that may cause actual results to differ
materially from those anticipated by the statements made herein.
Such risks and uncertainties include, risks related to the proposed
merger, including the fact that we may not complete the merger; we
do not have complete information about CytoBioscience, including
audited financial statements; the combined company will not be able
to continue operating without additional financing; possible
failure to realize anticipated benefits of the merger; costs
associated with the merger may be higher than expected; the merger
may result in disruption of the Company’s and CytoBioscience’s
existing businesses, distraction of management and diversion of
resources; delay in completion of the merger may significantly
reduce the expected benefits; and the market price of the Company’s
common stock may decline as a result of the merger. Other risks and
uncertainties relating to the Company include, among other things,
current negative operating cash flows and a need for additional
funding to finance our operating plan; the terms of any further
financing, which may be highly dilutive and may include onerous
terms; unexpected costs and operating deficits, and lower than
expected sales and revenues; uncertain willingness and ability of
customers to adopt new technologies and other factors that may
affect further market acceptance, if our product is not accepted by
our potential customers, it is unlikely that we will ever become
profitable; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners; the
impact of competition, the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of the
Company's technology; and management of growth and other risks and
uncertainties that may be detailed from time to time in the
Company's reports filed with the Securities and Exchange
Commission, which are available for review
at www.sec.gov. This is not a solicitation to buy or
sell securities and does not purport to be an analysis of the
Company's financial position. See the Company's most recent Annual
Report on Form 10-K, and subsequent reports and other filings
at www.sec.gov.
Company ContactSkyline Medical
Inc. Dr. Carl Schwartz 651-389-4800
Company
ContactCytoBioscienceJames R. Garvin,
PhD210-767-2727
Source: Uptick Newswire
Company Contact
Skyline Medical Inc.
Dr. Carl Schwartz
651-389-4800
CytoBiosciences
James R. Garvin, PhD
210-767-2727
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Apr 2023 to Apr 2024